1
|
Alzate D, Lopez-Osorio MC, Cortes-Mancera F, Navas MC, Orozco J. Detection of hepatitis E virus genotype 3 in wastewater by an electrochemical genosensor. Anal Chim Acta 2022; 1221:340121. [DOI: 10.1016/j.aca.2022.340121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Revised: 06/17/2022] [Accepted: 06/22/2022] [Indexed: 01/10/2023]
|
2
|
Kynurenic Acid Electrochemical Immunosensor: Blood-Based Diagnosis of Alzheimer's Disease. BIOSENSORS-BASEL 2021; 11:bios11010020. [PMID: 33445512 PMCID: PMC7827041 DOI: 10.3390/bios11010020] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 01/03/2021] [Accepted: 01/05/2021] [Indexed: 01/18/2023]
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder, characterized by a functional deterioration of the brain. Currently, there are selected biomarkers for its diagnosis in cerebrospinal fluid. However, its extraction has several disadvantages for the patient. Therefore, there is an urgent need for a detection method using sensitive and selective blood-based biomarkers. Kynurenic acid (KYNA) is a potential biomarker candidate for this purpose. The alteration of the KYNA levels in blood has been related with inflammatory processes in the brain, produced as a protective function when neurons are damaged. This paper describes a novel electrochemical immunosensor for KYNA detection, based on successive functionalization multi-electrode array. The resultant sensor was characterized by cyclic voltammetry (CV), chronoamperometry (CA), and electrochemical impedance spectroscopy (EIS). The proposed biosensor detects KYNA within a linear calibration range from 10 pM to 100 nM using CA and EIS, obtaining a limit of detection (LOD) of 16.9 pM and 37.6 pM in buffer, respectively, being the lowest reported LOD for this biomarker. Moreover, to assess our device closer to the real application, the developed immunosensor was also tested under human serum matrix, obtaining an LOD of 391.71 pM for CA and 278.8 pM for EIS with diluted serum.
Collapse
|
3
|
Alzate D, Cajigas S, Robledo S, Muskus C, Orozco J. Genosensors for differential detection of Zika virus. Talanta 2020; 210:120648. [DOI: 10.1016/j.talanta.2019.120648] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2019] [Revised: 12/12/2019] [Accepted: 12/13/2019] [Indexed: 01/26/2023]
|
4
|
Ouyang M, Di Carlo D. Nanoplasmonic swarm biosensing using single nanoparticle colorimetry. Biosens Bioelectron 2019; 132:162-170. [DOI: 10.1016/j.bios.2019.02.056] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2018] [Revised: 01/12/2019] [Accepted: 02/18/2019] [Indexed: 12/27/2022]
|
5
|
Tenaglia E, Ferretti A, Decosterd LA, Werner D, Mercier T, Widmer N, Buclin T, Guiducci C. Comparison against current standards of a DNA aptamer for the label-free quantification of tobramycin in human sera employed for therapeutic drug monitoring. J Pharm Biomed Anal 2018; 159:341-347. [PMID: 30025299 DOI: 10.1016/j.jpba.2018.06.061] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Revised: 06/14/2018] [Accepted: 06/29/2018] [Indexed: 12/28/2022]
Abstract
The use of DNA aptamers in biosensors for the quantification of pharmaceuticals in the clinics would help to overcome the limitations of antibody-based detection for small molecules. The interest for such systems is proven by the ever-increasing number of aptamer-based solutions for analytics proposed in the literature as proof-of-concept demonstrators. Despite such diversity, these platforms often lack a comparative assessment of their performances against the current standard of practice in the clinics when using real samples. We employed an aptamer against tobramycin discovered in our laboratory to quantify through surface plasmon resonance the concentration of the antibiotic in clinical samples obtained from patients treated with tobramycin and undergoing therapeutic drug monitoring. We then compared the performances of our detection strategy against the current standard of practice. Our results show how, using adequate calibration and matrix complexity reduction, DNA aptamer-based direct assays can assess clinically relevant concentrations of small molecules in patient serum and with good correlation to current standards used in the clinics.
Collapse
Affiliation(s)
- Enrico Tenaglia
- Ecole Polytechnique Fédérale de Lausanne, Institute of Bioengineering, Station 17, CH-1015 Lausanne, Switzerland
| | - Anna Ferretti
- Ecole Polytechnique Fédérale de Lausanne, Institute of Bioengineering, Station 17, CH-1015 Lausanne, Switzerland
| | - Laurent A Decosterd
- Laboratory of Clinical Pharmacology, Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland
| | - Dominique Werner
- Clinical Chemistry Laboratory, Lausanne University Hospital, Lausanne, Switzerland
| | - Thomas Mercier
- Laboratory of Clinical Pharmacology, Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland
| | - Nicolas Widmer
- Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland; Pharmacy of Eastern Vaud Hospitals, Vevey, Switzerland
| | - Thierry Buclin
- Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland
| | - Carlotta Guiducci
- Ecole Polytechnique Fédérale de Lausanne, Institute of Bioengineering, Station 17, CH-1015 Lausanne, Switzerland.
| |
Collapse
|
6
|
Peng D, Jiang N, Wang Y, Chen D, Liu Z, Yuan Z. Development and validation of an indirect competitive enzyme-linked immunosorbent assay for the detection of albendazole 2-aminosulfone residues in animal tissues. FOOD AGR IMMUNOL 2015. [DOI: 10.1080/09540105.2015.1086318] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
7
|
Stefan-van Staden RI, Bokretsion RG, van Staden JF, Aboul-Enein HY. Immunosensors in Clinical and Environmental Analysis. Crit Rev Anal Chem 2014. [DOI: 10.1080/10408347.2013.866035] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
8
|
Detection of benzimidazole carbamates and amino metabolites in liver by surface plasmon resonance-biosensor. Anal Chim Acta 2011; 700:41-8. [DOI: 10.1016/j.aca.2010.12.041] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2010] [Revised: 12/17/2010] [Accepted: 12/28/2010] [Indexed: 11/21/2022]
|
9
|
|
10
|
Benzimidazole carbamate residues in milk: Detection by Surface Plasmon Resonance-biosensor, using a modified QuEChERS (Quick, Easy, Cheap, Effective, Rugged and Safe) method for extraction. Anal Chim Acta 2009; 654:111-9. [PMID: 19854341 DOI: 10.1016/j.aca.2009.09.028] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2009] [Revised: 07/24/2009] [Accepted: 09/22/2009] [Indexed: 11/22/2022]
Abstract
A surface plasmon resonance (SPR) biosensor screening assay was developed and validated to detect 11 benzimidazole carbamate (BZT) veterinary drug residues in milk. The polyclonal antibody used was raised in sheep against a methyl 5(6)-[(carboxypentyl)-thio]-2-benzimidazole carbamate protein conjugate. A sample preparation procedure was developed using a modified QuEChERS method. BZT residues were extracted from milk using liquid extraction/partition with a dispersive solid phase extraction clean-up step. The assay was validated in accordance with the performance criteria described in 2002/657/EC. The limit of detection of the assay was calculated from the analysis of 20 known negative milk samples to be 2.7mugkg(-1). The detection capability (CCbeta) of the assay was determined to be 5mugkg(-1) for 11 benzimidazole residues and the mean recovery of analytes was in the range 81-116%. A comparison was made between the SPR-biosensor and UPLC-MS/MS analyses of milk samples (n=26) taken from cows treated different benzimidazole products, demonstrating the SPR-biosensor assay to be fit for purpose.
Collapse
|
11
|
Danaher M, De Ruyck H, Crooks SRH, Dowling G, O'Keeffe M. Review of methodology for the determination of benzimidazole residues in biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 845:1-37. [PMID: 16931192 DOI: 10.1016/j.jchromb.2006.07.046] [Citation(s) in RCA: 116] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2006] [Revised: 07/13/2006] [Accepted: 07/21/2006] [Indexed: 10/24/2022]
Abstract
Benzimidazoles are anthelmintic agents widely used in the treatment of parasitic infections in a range of species and as fungicidal agents in the control of spoilage of crops during storage and transport. In this paper, the more important benzimidazoles are introduced and their pharmacological effects and physiochemical properties discussed. The metabolism of these drugs is described relating to the occurrence and persistence of residues in biological matrices, providing information for selection of suitable matrices and target residues for testing. Methods for determination of benzimidazoles are reviewed for a range of biological matrices. The importance of selecting suitable extraction and clean-up procedures is discussed, along with the difficulties encountered in adapting single residue methods to multi-residue methods. The importance of suitable detection systems for determination of benzimidazoles, namely, screening, HPLC, GC and confirmatory methods is described in detail. The future for benzimidazole residue analysis is discussed, focusing on selection of appropriate residues for screening methods and protocols for confirmation of benzimidazole residues.
Collapse
Affiliation(s)
- Martin Danaher
- Teagasc, Ashtown Food Research Centre, Ashtown, Dublin 15, Ireland.
| | | | | | | | | |
Collapse
|
12
|
Masson JF, Battaglia TM, Khairallah P, Beaudoin S, Booksh KS. Quantitative Measurement of Cardiac Markers in Undiluted Serum. Anal Chem 2007; 79:612-9. [PMID: 17222027 DOI: 10.1021/ac061089f] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Two mycocardial infarction biomarkers, myoglobin (MG) and cardiac troponin I (cTnI), were quantified at biological levels and in undiluted serum without sample pretreatment using surface plasmon resonance (SPR) sensors. To achieve detection of biomarkers in undiluted serum (72 mg/mL total protein concentration), minimization of the nonspecific signal from the serum protein was achieved by immobilizing the antibody for the biomarkers on an N-hydroxysuccinimide activated 16-mercaptohexadecanoic acid self-assembled monolayer. This monolayer reduces the nonspecific signal from serum proteins in such a manner that short exposure of the sensor to serum prior to analysis prevents any further nonspecific adsorption during analysis. Thus, sensing of MG and cTnI was achieved on the basis of the difference between signals from the active sensor and a reference sensor that captured background interference. This resulted in direct measurement of these biomarkers in undiluted serum. Detection limits for both markers were below 1 ng/mL, which is below the threshold needed to detect myocardial infarction. Detecting biomarkers in the low ng/mL range without signal amplification in such a complex matrix as serum corresponds to a selectivity of 108. The root-mean-square-error (RMSE) of calibration was below 2 ng/mL.
Collapse
Affiliation(s)
- Jean-Francois Masson
- Department of Chemistry and Biochemistry, Arizona State University, Mail Code 1604, Tempe, Arizona 85287-1604, USA
| | | | | | | | | |
Collapse
|
13
|
Rich RL, Myszka DG. A survey of the year 2002 commercial optical biosensor literature. J Mol Recognit 2004; 16:351-82. [PMID: 14732928 DOI: 10.1002/jmr.649] [Citation(s) in RCA: 70] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
We have compiled 819 articles published in the year 2002 that involved commercial optical biosensor technology. The literature demonstrates that the technology's application continues to increase as biosensors are contributing to diverse scientific fields and are used to examine interactions ranging in size from small molecules to whole cells. Also, the variety of available commercial biosensor platforms is increasing and the expertise of users is improving. In this review, we use the literature to focus on the basic types of biosensor experiments, including kinetics, equilibrium analysis, solution competition, active concentration determination and screening. In addition, using examples of particularly well-performed analyses, we illustrate the high information content available in the primary response data and emphasize the impact of including figures in publications to support the results of biosensor analyses.
Collapse
Affiliation(s)
- Rebecca L Rich
- Center for Biomolecular Interaction Analysis, University of Utah, Salt Lake City, UT 84132, USA
| | | |
Collapse
|
14
|
Johansson MA, Hellenas KE. Matrix effects in immunobiosensor determination of clenbuterol in urine and serum. Analyst 2004; 129:438-42. [PMID: 15116237 DOI: 10.1039/b316723b] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
The construction of immunochemical inhibition assays for beta-agonist and hormone residues have previously been described. In the present work the beta-agonist assay was further optimised for application to biological samples, using urine as the main model matrix. Matrix interferences with the antigen-antibody interaction and non-specific binding (NSB) of matrix components to the sensor surface were systematically studied. A full factorial design experiment was employed for evaluating the effects of assay buffer composition. In addition, the influence of antibody concentration and sample dilution on the matrix background was investigated. NSB from urine was highly affected by buffer pH and salt concentration, while buffer composition had little effect on matrix interferences with the antigen-antibody interaction. Ultra-filtration efficiently prevented NSB from urine and serum samples. Increased antibody dilution reduced the matrix background while sample dilution had an opposite effect.
Collapse
|